carmustine has been researched along with Gliosarcoma in 29 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Gliosarcoma: Rare mixed tumors of the brain and rarely the spinal cord which contain malignant neuroectodermal (glial) and mesenchymal components, including spindle-shaped fibrosarcoma cells. These tumors are highly aggressive and present primarily in adults as rapidly expanding mass lesions. They may arise in tissue that has been previously irradiated. (From Br J Neurosurg 1995 Apr;9(2):171-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of methylguanine methyltransferase (MGMT) depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and the impact of methylation status in adults with glioblastoma multiforme (GBM) and gliosarcoma." | 9.20 | A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. ( Blumenthal, DT; Moore, DF; Padula, GD; Rankin, C; Rushing, EJ; Schulman, SB; Sloan, AE; Spence, AM; Stelzer, KJ; Wade, ML, 2015) |
| "To determine the efficacy of methylguanine methyltransferase (MGMT) depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and the impact of methylation status in adults with glioblastoma multiforme (GBM) and gliosarcoma." | 5.20 | A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. ( Blumenthal, DT; Moore, DF; Padula, GD; Rankin, C; Rushing, EJ; Schulman, SB; Sloan, AE; Spence, AM; Stelzer, KJ; Wade, ML, 2015) |
| "To investigate the safety of thrice-daily hyperfractionated radiotherapy (RT) given in conjunction with BCNU (carmustine) in high-grade gliomas." | 5.10 | Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas. ( Buckner, JC; Dinapoli, RP; Earle, JD; O'Fallon, J; Rao, RD; Thomé, SD, 2002) |
| "To investigate the ability of systemically delivered BCNU to enhance the activity of either systemically delivered irinotecan (CPT-11) or locally delivered camptothecin from a biodegradable polymer for treatment of an intracranial 9L gliosarcoma." | 3.72 | Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. ( Brem, H; Moriarity, JL; Renard, VM; Storm, PB; Tyler, B; Weingart, JD; Wilentz, RE, 2004) |
| ") carmustine is highly effective for the treatment of intracranial 9L gliosarcoma in tumors." | 3.70 | Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats. ( Kleinschmidt-DeMasters, BK; Kong, Q; Lillehei, KO, 1998) |
| "This study was designed to explore the question of whether minocycline, a semisynthetic tetracycline shown to inhibit tumor-induced angiogenesis, could control the growth of the rat intracranial 9L gliosarcoma." | 3.69 | The role of minocycline in the treatment of intracranial 9L glioma. ( Brem, H; Sipos, EP; Weingart, JD, 1995) |
| " BCNU delivered from the MEMS device showed dose-dependent inhibiting effect on the tumor growth in the BCNU dosage range of 0." | 1.33 | In vivo delivery of BCNU from a MEMS device to a tumor model. ( Brem, H; Cima, MJ; Ho Duc, HL; Langer, R; Li, Y; Tupper, M; Tyler, B; Williams, T, 2005) |
| " A dose-response relationship for BCNU was observed (hazard ratio 0." | 1.30 | Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. ( Brem, H; Burger, PC; Piantadosi, S; Sipos, EP; Tyler, B, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (24.14) | 18.2507 |
| 2000's | 19 (65.52) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blumenthal, DT | 1 |
| Rankin, C | 1 |
| Stelzer, KJ | 1 |
| Spence, AM | 1 |
| Sloan, AE | 1 |
| Moore, DF | 1 |
| Padula, GD | 1 |
| Schulman, SB | 1 |
| Wade, ML | 1 |
| Rushing, EJ | 1 |
| Galbán, CJ | 2 |
| Bhojani, MS | 2 |
| Lee, KC | 3 |
| Meyer, CR | 2 |
| Van Dort, ME | 1 |
| Kuszpit, KK | 1 |
| Koeppe, RA | 1 |
| Ranga, R | 1 |
| Moffat, BA | 2 |
| Johnson, TD | 4 |
| Chenevert, TL | 6 |
| Rehemtulla, A | 6 |
| Ross, BD | 6 |
| Hoff, BA | 1 |
| Kwee, TC | 1 |
| Le Bihan, D | 1 |
| Rhines, LD | 2 |
| Sampath, P | 2 |
| DiMeco, F | 1 |
| Lawson, HC | 1 |
| Tyler, BM | 4 |
| Hanes, J | 1 |
| Olivi, A | 1 |
| Brem, H | 10 |
| Zhang, YP | 1 |
| Xu, XN | 1 |
| Wang, JH | 1 |
| Lu, G | 1 |
| Liu, P | 1 |
| Su, TF | 1 |
| Liu, HS | 1 |
| Qi, JB | 1 |
| Gao, B | 1 |
| Frazier, JL | 1 |
| Wang, PP | 1 |
| Case, D | 1 |
| Pradilla, G | 1 |
| Weingart, JD | 3 |
| Horvath, Z | 1 |
| Höchtl, T | 1 |
| Bauer, W | 1 |
| Fritzer-Szekeres, M | 1 |
| Elford, HL | 1 |
| Szekeres, T | 1 |
| Tihan, T | 1 |
| Storm, PB | 1 |
| Renard, VM | 1 |
| Moriarity, JL | 1 |
| Tyler, B | 3 |
| Wilentz, RE | 1 |
| Saito, R | 1 |
| Bringas, J | 1 |
| Mirek, H | 1 |
| Berger, MS | 1 |
| Bankiewicz, KS | 1 |
| Lee, JS | 2 |
| An, TK | 1 |
| Chae, GS | 2 |
| Jeong, JK | 1 |
| Cho, SH | 1 |
| Lee, HB | 2 |
| Khang, G | 2 |
| Schepkin, VD | 3 |
| Sharma, S | 1 |
| Kumar, M | 2 |
| Stojanovska, J | 2 |
| Kim, SH | 1 |
| Seo, KS | 1 |
| Kim, MS | 1 |
| Li, Y | 1 |
| Ho Duc, HL | 1 |
| Williams, T | 1 |
| Tupper, M | 1 |
| Langer, R | 2 |
| Cima, MJ | 2 |
| Chen, M | 1 |
| Kariaapper, MS | 1 |
| Hamstra, DA | 1 |
| Hall, DE | 1 |
| Blaivas, M | 1 |
| Kuszpit, K | 2 |
| Muthuswami, M | 1 |
| Zarnitsyn, VG | 1 |
| Kamaev, PP | 1 |
| Prausnitz, MR | 1 |
| Kim, GY | 1 |
| Tupper, MM | 1 |
| Karp, JM | 1 |
| Langer, RS | 1 |
| Kimler, BF | 1 |
| Steen, RG | 1 |
| Kitagishi, K | 1 |
| Morgan, K | 1 |
| Sipos, EP | 2 |
| Wu, MP | 1 |
| Tamada, JA | 1 |
| Buahin, KG | 1 |
| Piantadosi, S | 1 |
| Burger, PC | 1 |
| Kong, Q | 1 |
| Kleinschmidt-DeMasters, BK | 1 |
| Lillehei, KO | 1 |
| Khil, MS | 1 |
| Kolozsvary, A | 1 |
| Apple, M | 1 |
| Kim, JH | 1 |
| Dolan, ME | 1 |
| Weingart, J | 1 |
| Schäfer, C | 1 |
| Fels, C | 1 |
| Brucke, M | 1 |
| Holzhausen, HJ | 1 |
| Bahn, H | 1 |
| Wellman, M | 1 |
| Visvikis, A | 1 |
| Fischer, P | 1 |
| Rainov, NG | 1 |
| Rao, RD | 1 |
| Thomé, SD | 1 |
| O'Fallon, J | 1 |
| Earle, JD | 1 |
| Dinapoli, RP | 1 |
| Buckner, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma[NCT00017147] | Phase 3 | 183 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for carmustine and Gliosarcoma
| Article | Year |
|---|---|
A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Diseases; Carm | 2002 |
27 other studies available for carmustine and Gliosarcoma
| Article | Year |
|---|---|
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dexamethasone; Diffusion Magnetic Reson | 2010 |
Assessment of multiexponential diffusion features as MRI cancer therapy response metrics.
Topics: Algorithms; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Diffusion Magn | 2010 |
Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
Topics: Animals; Biodegradation, Environmental; Biological Availability; Brain Neoplasms; Carmustine; Chondr | 2003 |
[Study on drug delivery of the 3H-BCNU polylacties acid released agents on gliosarcoma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Gliosarcoma; Male; | 2003 |
Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2003 |
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 2004 |
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Topics: Animals; Brain Neoplasms; Camptothecin; Carmustine; Cell Line, Tumor; Enzyme Inhibitors; Female; Gli | 2004 |
Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Culture Techniques; Ce | 2004 |
Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Line, Tumor; Cell Survival; Drug Evaluation, Precli | 2005 |
Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Gliosarc | 2005 |
Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dru | 2005 |
In vivo delivery of BCNU from a MEMS device to a tumor model.
Topics: Animals; Antineoplastic Agents, Alkylating; Carbon Radioisotopes; Carmustine; Chemistry, Pharmaceuti | 2005 |
Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Flow Velocity; Blood Volume; Brain Neoplasms; Carm | 2006 |
Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2006 |
Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Diffusion; Drug Resis | 2006 |
Ultrasound-enhanced chemotherapy and gene delivery for glioma cells.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cell Survival; Combined Modality Therapy; DNA | 2007 |
Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Chemistry, Pharmace | 2007 |
The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Bleomycin; Brain Neoplasms; Carmustine; C | 1994 |
In vivo measurement of tumor blood oxygenation by near-infrared spectroscopy: immediate effects of pentobarbital overdose or carmustine treatment.
Topics: Animals; Brain Neoplasms; Carmustine; Cerebrovascular Circulation; Gliosarcoma; Hemoglobins; Oxygen; | 1994 |
The role of minocycline in the treatment of intracranial 9L glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modal | 1995 |
In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy.
Topics: Animals; Biodegradation, Environmental; Brain Neoplasms; Carmustine; Cellulose, Oxidized; Decanoic A | 1994 |
Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell | 1995 |
Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Carmustine; Cell Line; Con | 1997 |
Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cath | 1998 |
Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Carmustine; Cobalt Radiois | 2000 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
Gamma-glutamyl transferase expression in higher-grade astrocytic glioma.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain; Carmustine; | 2001 |